论文部分内容阅读
目的观察初治涂阳肺结核患者肺泰胶囊联合2HRZE/4HR化疗治疗的效果。方法选取某医院126例初治涂阳肺结核患者,随机分为治疗组和对照组。对照组予常规抗结核药物治疗,治疗方案为2HRZE/4HR;治疗组在此基础上加服肺泰胶囊,比较两组患者在治疗不同时期的痰菌阴转率、病灶吸收率及空洞关闭率、临床症状缓解率及不良反应发生率差异。结果共纳入113例患者,治疗组58例,对照组55例。治疗组治疗2、5、6个月末的痰菌阴转率分别为75.86%、94.83%和100.00%,均高于同期对照组的52.73%、81.82%和90.91%(P<0.05)。治疗2个月末、6个月末治疗组病灶吸收总有效率分别为81.03%和98.28%,均高于对照组的43.64%和70.91%(P<0.01);治疗组空洞闭合及缩小的总有效率分别为70.00%和95.00%,均高于对照组的27.03%和70.27%(P<0.01)。治疗1个月后,治疗组患者咳嗽、咳痰、咯血等临床症状缓解率均高于对照组(P<0.05)。治疗组和对照组患者药物不良反应发生率分别为24.14%和29.09%,差异无统计学意义(P>0.05)。结论肺泰胶囊联合2HRZE/4HR化疗对初治涂阳肺结核患者痰菌阴转,肺部病灶的吸收,空洞的缩小、闭合和咳嗽、咳痰等临床症状缓解有明显效果。
Objective To observe the effect of treatment of pulmonary smear positive pulmonary tuberculosis combined with 2HRZE / 4HR chemotherapy. Methods A total of 126 newly diagnosed smear positive pulmonary tuberculosis patients in a hospital were selected and randomly divided into treatment group and control group. The control group was treated with conventional antituberculosis drugs, and the treatment regimen was 2HRZE / 4HR. On the basis of this, the treatment group was additionally given Taifei Capsule. The sputum negative conversion rate, the rate of lesion absorption and the void closure rate were compared between the two groups , The rate of clinical symptoms and the incidence of adverse reactions. Results A total of 113 patients were enrolled, 58 in the treatment group and 55 in the control group. The sputum negative conversion rates of the treatment group at the end of 2, 5 and 6 months were 75.86%, 94.83% and 100.00%, respectively, which were all higher than those of the control group (52.73%, 81.82% and 90.91%, P <0.05). At the end of 2 months of treatment, the total effective rates of the lesions in the treatment group were 81.03% and 98.28%, respectively, which were higher than those in the control group (43.64% and 70.91%, P <0.01). The total effective rate of the cavity closure and reduction in the treatment group 70.00% and 95.00% respectively, which were higher than those of the control group (27.03% and 70.27%, P <0.01). After 1 month of treatment, the relief rate of clinical symptoms such as cough, expectoration and hemoptysis in the treatment group were higher than those in the control group (P <0.05). The incidences of adverse drug reactions in the treatment group and the control group were 24.14% and 29.09%, respectively, with no significant difference (P> 0.05). Conclusion The combination of Feitai capsule and 2HRZE / 4HR chemotherapy has obvious effect on relieving clinical symptoms such as sputum negative conversion, lung lesion absorption, cavity shrinkage, closure and cough and expectoration in newly smear positive pulmonary tuberculosis patients.